# ExeVir Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exevir-bio

- Industry: Biotechnology
- Headquarters: Ghent, Belgium
- Website: www.exevir.com
- Total disclosed funding: $39M
- Latest round: Series A (Mar 19, 2021)
- Investors on record: 9

## About

Based in Belgium, and founded in 2020, ExeVir Bio BV operates as a biotech firm that develops nanobody therapies for various infectious diseases. The company is a spin-out of VIB and was founded by Xavier Saelens and Nico Callewaert. In January 2023, ExeVir Bio BV raised EUR 25 million in venture debt funding from the European Investment Bank. As of 2023, the company’s CEO is Torsten Mummenbrauer.

The company develops viral infection medicines using clinically validated VHH technology. VHH72-Fc, the lead asset, binds to a unique epitope conserved in SARS-CoV-1 and SARS-CoV-2 viruses and stops them from entering the cell. This method could be used both therapeutically and prophylactically. Slowing viral multiplication in the lungs, reducing inflammation, and giving patients critical time to establish their own productive immune response could all be aided by therapeutic use. Prophylactic use could help ringfence an outbreak, safeguard healthcare personnel, and help patients who are at higher risk of severe COVID-19 sickness.

ExeVir Bio BV plans to use the funds raised in January 2023 to advance its product and support a clinical trial.

## Funding rounds

- Series A, Mar 19, 2021, $22M — Vives, VIB, SFPI-FPIM, Sambrinvest, Noshaq, Fund+, SRIW, V-Bio Ventures, UCB Ventures
- Series A, Jul 28, 2020, $17M — VIB, SFPI-FPIM, Fund+, V-Bio Ventures, UCB Ventures

## Investors

- VIB — Series A
- SFPI-FPIM — Series A
- Fund+ (https://capitalatlas.ai/funds/fund) — Series A
- V-Bio Ventures (https://capitalatlas.ai/funds/v-bio-ventures) — Series A
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A
- Vives (https://capitalatlas.ai/funds/vives) — Series A
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series A
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- SRIW — Series A